Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
6-1-2022

Clonal dynamics of haematopoiesis across the human lifespan
Emily Mitchell
David H Spencer
et al

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Article

Clonal dynamics of haematopoiesis across
the human lifespan
https://doi.org/10.1038/s41586-022-04786-y
Received: 16 August 2021
Accepted: 19 April 2022
Published online: 1 June 2022
Open access

Emily Mitchell1,2,3, Michael Spencer Chapman1,10, Nicholas Williams1,10, Kevin J. Dawson1,10,
Nicole Mende2, Emily F. Calderbank2, Hyunchul Jung1, Thomas Mitchell1, Tim H. H. Coorens1,
David H. Spencer4, Heather Machado1, Henry Lee-Six1, Megan Davies5, Daniel Hayler2,
Margarete A. Fabre1,2,3, Krishnaa Mahbubani6,7, Federico Abascal1, Alex Cagan1,
George S. Vassiliou1,2,3, Joanna Baxter3, Inigo Martincorena1, Michael R. Stratton1,
David G. Kent8, Krishna Chatterjee9, Kourosh Saeb Parsy6,7, Anthony R. Green2,3,
Jyoti Nangalia1,2,3,11 ✉, Elisa Laurenti2,3,11 ✉ & Peter J. Campbell1,2,11 ✉

Check for updates

Age-related change in human haematopoiesis causes reduced regenerative capacity1,
cytopenias2, immune dysfunction3 and increased risk of blood cancer4–6, but the
reason for such abrupt functional decline after 70 years of age remains unclear. Here
we sequenced 3,579 genomes from single cell-derived colonies of haematopoietic
cells across 10 human subjects from 0 to 81 years of age. Haematopoietic stem cells or
multipotent progenitors (HSC/MPPs) accumulated a mean of 17 mutations per year
after birth and lost 30 base pairs per year of telomere length. Haematopoiesis in
adults less than 65 years of age was massively polyclonal, with high clonal diversity
and a stable population of 20,000–200,000 HSC/MPPs contributing evenly to blood
production. By contrast, haematopoiesis in individuals aged over 75 showed
profoundly decreased clonal diversity. In each of the older subjects, 30–60% of
haematopoiesis was accounted for by 12–18 independent clones, each contributing
1–34% of blood production. Most clones had begun their expansion before the subject
was 40 years old, but only 22% had known driver mutations. Genome-wide selection
analysis estimated that between 1 in 34 and 1 in 12 non-synonymous mutations were
drivers, accruing at constant rates throughout life, affecting more genes than
identified in blood cancers. Loss of the Y chromosome conferred selective benefits in
males. Simulations of haematopoiesis, with constant stem cell population size and
constant acquisition of driver mutations conferring moderate fitness benefits,
entirely explained the abrupt change in clonal structure in the elderly. Rapidly
decreasing clonal diversity is a universal feature of haematopoiesis in aged humans,
underpinned by pervasive positive selection acting on many more genes than
currently identified.

The age-related mortality curve for modern humans is an outlier across
the tree of life, with an abrupt increase in mortality after the average
lifespan7, leading to surprisingly low variance in age at death8. Studies
of ageing at the cellular level have demonstrated that accumulation of
molecular damage across the lifespan is gradual and lifelong, including
telomere attrition, somatic mutation, epigenetic change and oxidative
or replicative stress9. It remains unresolved how such gradual accumulation of molecular damage can translate into an abrupt increase
in mortality after 70 years of age.
Sequencing of blood samples from population cohorts has revealed
an age-related increase in acquired mutations in genes that cause

myeloid neoplasms4,5,10–12, known as driver mutations. This phenomenon is called clonal haematopoiesis, and reaches 10–20% prevalence4,5,10–12 or higher13 after 70 years of age, but the driver mutations
typically account for only a small fraction of haematopoiesis (less
than 5% of cells). Some elderly individuals show evidence of clonal
expansions even in the absence of known driver mutations14–16. Deep
sequencing of bulk blood samples, as used in these studies, struggles to elucidate clonal relationships among cells and is insensitive to
mutations that are present in a low proportion (below 1–5%) of blood
cells—as a result, we lack an unbiased, high-resolution model for the
clonal dynamics of human haematopoiesis with ageing. Whole-genome
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Fig. 1 | Mutational burden in normal HSC/MPPs. a, Bar plot showing the
numbers of colonies sequenced from each tissue and cell type for each donor in
the study. Age and sex (F, female; M, male) are indicated below the donor ID.
b, Burden of single nucleotide variants across the donor cohort. The points
represent individual HSC/MPP colonies (n = 3,361) and are coloured by donor
as indicated in a. The grey line represents a regression of age with mutation
burden, with shading indicating the 95% confidence interval. c, Burden of
small indels across the donor cohort. d, Bar plot showing the number of
independently acquired structural variants (SVs) per colony sequenced in each
donor. The absolute number of structural variants is shown at the top of each
bar. e, Bar plot showing the number of independently acquired autosomal copy

number aberrations (CNAs) per colony sequenced in each donor. The absolute
number of copy number aberrations is shown at the top of each bar. f, Bar plot
showing the number of independently acquired Y chromosome copy number
aberrations sequenced in each male donor. The absolute number of copy
number aberrations is shown at the top of each bar. g, Telomere length across
the donor cohort, including only those samples sequenced on the HiSeq X10
platform. Each point represents a single HSC/MPP colony. Two outlying points
for CB001 are not shown (telomere lengths 16,037 bp and 21,155 bp). In
b, c, g, boxes overlaid indicate the median and interquartile range and
whiskers denote the minimum of either the range or 25th and 75th centile plus
1.5× interquartile range.

sequencing of colonies grown from single cells circumvents these limitations of bulk sequencing17–19. We sequenced whole genomes of 3,579
single cell-derived haematopoietic colonies from 10 healthy individuals
spanning the human lifespan, revealing an abrupt and universal loss
of clonal diversity after the age of 70 years.

Single immunophenotypic HSC/MPPs (Lin−CD34+CD38−CD45RA−)
were sorted using flow cytometry and cultured (Extended Data Fig. 1b).
Overall, 42–89% of sorted HSC/MPPs produced colonies (Extended
Data Fig. 1c), suggesting that the sequenced colonies were a representative sample of the HSC/MPP population in each individual, as
supported by analysis of cell surface markers (Extended Data Fig. 1d).
Haematopoietic progenitor cells (HPCs) (Lin−CD34+CD38+) were also
flow-sorted for four individuals.
We performed whole-genome sequencing at average sequencing
depths of 14× on 224–453 colonies per individual. We excluded 17 colonies
with low coverage, 34 technical duplicates and 7 colonies derived from
more than a single cell (Extended Data Fig. 2a–c). The final dataset comprised whole genomes from 3,579 colonies, of which 3,361 were derived
from HSC/MPPs and 218 were derived from HPCs. Raw mutation burdens were corrected for sequencing depth using asymptotic regression
(Extended Data Fig. 2d). Single-base substitution spectra were consistent
with previous results17,18,21 (Extended Data Fig. 2e, f). Phylogenetic trees
for each adult individual were constructed—terminal branch lengths

Whole-genome sequencing of HSC colonies
We obtained samples from 10 individuals, with no known haematological disease, aged between 0 and 81 years (Extended Data Fig. 1a,
Supplementary Table 1). One subject (KX002, a 38-year-old male) had
inflammatory bowel disease treated with azathioprine and another
(SX001, a 48-year0old male) had selenoprotein deficiency20, a genetic
disorder not known to affect haemapoietic stem cell (HSC) dynamics.
Stem cells were obtained from cord blood for the two neonates, and
from bone marrow and/or peripheral blood for adult donors (Fig. 1a).
Bone marrow samples were obtained peri-mortem, enabling sampling
of large volumes (50–80 ml) from multiple vertebrae.
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were then corrected for sequencing depth, followed by normalization to
identical total root-to-tip branch lengths and scaling to chronological time
(Extended Data Fig. 3). Benchmarking of the phylogenies included assessments of internal consistency, stability across phylogenetic inference
algorithms and robustness to bootstrapping (Supplementary Methods).
All code for variant filtering, phylogenetic reconstruction, benchmarking and downstream analyses are available in the Supplementary Code.

Mutation burden and telomere lengths
Consistent with previous data18,22, point mutations accumulated linearly
in HSC/MPPs throughout life, at a rate of 16.8 substitutions per cell per
year (95% confidence interval 16.5–17.1; Fig. 1b) and 0.71 insertion–
deletion mutations (indels) per cell per year (95% confidence interval
0.65–0.77; Fig. 1c). We found no significant difference in mutation burden between HSC/MPPs and HPCs (Extended Data Fig. 4a). Structural
variants were rare, with only 1–17 events observed in each individual,
mostly deletions, correlating with age (Fig. 1d, Extended Data Fig. 4b,
Supplementary Table 3). Autosomal copy number aberrations were rare
at all ages and comprised either copy-neutral loss-of-heterozygosity
events or tetrasomies (Fig. 1e). By contrast, loss of the Y chromosome
was frequent in males, increasing with age as previously shown23
(Fig. 1f); no corresponding examples of loss of the inactive X chromosome were observed in older females.
We estimated telomere lengths for the 1,505 HSC/MPP colonies
from 7 individuals sequenced on Hiseq X10 (Fig. 1g). As previously
reported24,25, telomere lengths decreased steadily with age, at an average attrition rate of 30.8 base pairs (bp) per year in adult life (95% confidence interval 13.2–48.4), close to published estimates of 39 bp per
year from bulk granulocytes25. By sequencing single cell-derived colonies, we can estimate the variance and distribution in telomere lengths
among cells with a greater resolution than is possible with bulk populations. In cord blood and young adults, a small proportion of HSC/MPPs
had unexpectedly long telomeres, a proportion that decreased with
age (Extended Data Fig. 4c). Given that telomeres shorten at cell division, these outlier cells have presumably undergone fewer historic cell
divisions. A rare population of infrequently dividing dormant HSCs has
been described in the mouse26,27 and our telomere data are consistent
with an analogous population in humans, especially early in life.

HSC clonal dynamics after 70 years of age
The phylogenetic trees generated here depict the lineage relationships
among ancestors of the sequenced stem and progenitor cells. Given the
consistent, linear rate of mutation accumulation across the lifespan, we
scaled the raw phylogenetic trees (Extended Data Fig. 3d) to chronological
time to study clonal dynamics of HSC/MPPs across the lifespan (Figs. 2, 3,
Extended Data Fig. 5). Branch points in the tree (‘coalescences’) define
historic stem cell divisions. In taxonomy, a clade is defined as a group of
organisms descended from a single common ancestor—in the context of
somatic cells, this represents a clone, and its size can be estimated from
the fraction of colonies derived from that ancestor. Here, we define an
‘expanded clade’ as a postnatal ancestral lineage whose descendants
contributed more than 1% of colonies at the time of sampling.
Phylogenetic trees of the 4 adults aged below 65 years showed that
healthy haematopoiesis in young and middle-aged individuals is highly
polyclonal (Fig. 2, Extended Data Fig. 5a). Despite sequencing 361–408
colonies per individual, we found at most a single expanded clade in
each sample, and the two that we observed contributed less than 2% of
all haematopoiesis in those individuals. Only four known or possible
driver point mutations were identified, none of which occurred in the
two expanded clades.
Phylogenetic trees for the 4 adults aged over 70 years were qualitatively different (Fig. 3, Extended Data Fig. 5b), with an oligoclonal
pattern of haematopoiesis. In each elderly individual, we found 12–18

independent clones established between birth and 40 years of age that
each contributed between 1% and 34% of colonies sequenced, most in the
1–3% range. Collectively, these clones summed to a significant proportion of all blood production in our elderly research subjects—between
32% and 61% of all colonies sequenced derived from the expanded clades.
Only a minority of clonal expansions in the elderly individuals carried known driver mutations. Although we identified mutations in
DNMT3A, TET2 and CBL, mutations in the top 17 myeloid driver genes
could explain only 10 out of 58 expanded clades with a clonal fraction
above 1%. We identified only 3 additional mutations when we extended
the analysis to a wider set of 92 genes implicated in myeloid neoplasms28
(Supplementary Tables 4, 5), leaving 45 clonal expansions unexplained.

HSC/MPP population size in young donors
The frequency of branch points in phylogenetic trees in a neutrally
evolving, well-mixed population of somatic cells is determined primarily by the product of population size and time between symmetric
self-renewal cell divisions (Nτ)—both smaller populations and more
frequent symmetric divisions increase coalescences. In young adults, in
whom clonal selection has had minimal impact on phylogenetic trees,
we can exploit this property to estimate the lifelong trajectory of population size dynamics29 (Fig. 4a). There is a rapid increase in estimated Nτ
in utero, reaching a plateau during infancy and early childhood. This is
evidenced by a high density of coalescences in the first approximately
50 mutations along molecular time (Fig. 2, Extended Data Fig. 5a); the
cord blood colonies we sequenced had a mean of 55 mutations.
Using both phylodynamic and approximate Bayesian computation
(ABC) modelling, we estimate that steady-state haematopoiesis plateaus
at an Nτ of about 100,000 HSC-years (Fig. 4). This was consistent across
all 4 young adults, with individual estimates and 95% confidence intervals in the range 50,000–250,000, matching published estimates17,30.
To estimate N (the HSC population size), we require an estimate of
τ, the time between symmetric HSC self-renewal divisions. Previous
estimates17,25,31 of τ for HSCs range between 0.6 and 6 years. Telomeres in
HSCs shorten at mitosis by 30–100 bp per cell division32, and therefore
provide an independent means to estimate the number of historic cell
divisions an HSC has undergone. We estimated that HSC/MPP telomeres
shorten at a rate of 30 bp per year (Fig. 1g)—this bounds the number of
symmetric cell divisions to at most 1–2 divisions per year. Two recent
studies in mice have shown that symmetric divisions predominate
within the HSC pool, accounting for 80–100% of all HSC divisions33,34.
Together, these data are most consistent with adult haematopoiesis
being maintained by a population of 20,000–200,000 long-term HSCs.
In the young individuals, and indeed in the four elderly individuals,
we noted a sparsity of branch points towards the tips of the phylogenies
compared to earlier ages—this emerged consistently about 10–15 years
of molecular time before sampling, irrespective of the subject’s age.
We hypothesize that this pattern arises from a large, short-term HSC/
MPP compartment that contributes to haematopoiesis for 10–15 years.
Owing to its short-term contribution, the effects of this compartment
would only be evident at the tips of the phylogeny, with earlier branches
reflecting dynamics in the long-term HSC compartment. A substantially
larger population size for these short-term HSC/MPPs would explain
why the density of coalescences decreases towards the tips of the trees
(Extended Data Fig. 6). The mouse short-term HSC/MPP compartment
is known to sustain steady-state haematopoiesis without significant
input from the long-term HSC compartment for many months35,36, a
similar proportion of a mouse’s lifespan as 10–15 years is for a human.

HSC dynamics in the elderly
We observed a qualitative change in the population structure of HSCs
in the elderly, with an abrupt increase in the frequency of expanded
clones and the total fraction of haematopoiesis they generate (Fig. 5a).
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Fig. 2 | HSPC phylogenies for three young adult donors. a–c, Phylogenies
were constructed for a 29-year-old (a), a 38-year-old (b) and a 63-year-old (c)
male donor using shared mutation data and the algorithm MPBoot (Methods).
Branch lengths are proportional to the number of mutations assigned to the
branch—terminal branches have been corrected for sequence coverage, and
overall root-to-tip branch lengths have been normalized to the same total
length (because all colonies were collected from a single time point). The y-axis
is scaled to chronological time using the somatic mutation rate as a molecular
clock, with age 0 (representing birth) set at 55 mutations (as estimated from
our cord blood colonies). Each tip on a phylogeny represents a single colony,
with the respective numbers of colonies of each cell and tissue type recorded at

the top. Onto these trees, we have layered clone and colony-specific
phenotypic information. We have highlighted branches on which we have
identified known oncogenic drivers (solid line) and possible oncogenic drivers
(dashed line) in one of 17 clonal haematopoiesis genes (Supplementary
Table 4), coloured by gene. Branches with autosomal copy number alterations
are highlighted with a black dashed line. A heat map at the bottom of each
phylogeny highlights colonies from known driver clades coloured by gene,
expanded clades (defined as those with a clonal fraction above 1%) in blue and
colonies with loss of the Y chromosome in pink (males only). BM, bone marrow;
PB, peripheral blood; CN_LOH, copy-neutral loss of heterozygosity. The
phylogeny of the fourth young adult donor is shown in Extended Data Fig. 5a.

The Shannon index, which measures clonal diversity, showed a precipitous decline in diversity after age 70 (Fig. 5b). Although this change
was evident only in the elderly, the branch points in the phylogenetic
tree that underpinned the clonal expansions occurred much earlier in
life, between childhood and middle age (Extended Data Fig. 7). There
are several possible explanations for these observations, including
age-related changes in population size, changes in spatial patterning
of HSCs and cell-autonomous variation in selective fitness.
Using ABC, we explored whether changes in population size, most
probably a population bottleneck occurring in mid-life, could explain
the observed trees (Extended Data Fig. 7b). However, although they
accurately recapitulated trees observed in subjects over 65 years of age,
even the 1% most closely matching phylogenies from these simulations
poorly replicated those observed in the elderly (Extended Data Fig. 8).
Essentially, observed trees in the elderly showed marked asymmetry
among clones, with a few large clades but also numerous ‘singleton’
branches. By contrast, simulations of variable population sizes generated trees with more evenly distributed coalescences among clades.
Theoretically, altered spatial patterning of HSCs could also explain the
changes in phylogeny—if, for example, HSCs circulated less frequently
with ageing, the bone marrow population would be less well mixed and

therefore show increased density of coalescences in a bone marrow sample obtained from just a few vertebrae. To address this, we sequenced both
marrow and peripheral blood HSCs from the 81-year-old subject. Peripheral blood colonies recaptured most of the expanded clades evident in
marrow and at similar clonal fractions, suggesting that spatial segregation
is not sufficient to explain the changes with ageing (Extended Data Fig. 7c).
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Genetic evidence for positive selection
The asymmetry of population structure in the elderly suggests that
clone-specific factors could lead to differential expansion among HSCs.
Positively selected driver mutations are one, but not the only, possible
cause of clone-specific variation in expansion rates; for example, epigenetic change, telomere shortening and microenvironment ageing could
also contribute. Furthermore, it is unclear whether driver mutations
acquired randomly throughout life could lead to such a qualitative
change in population structure after the age of 70. To address these
questions, we used two approaches: one based on genetic analysis of
selection and one based on ABC models.
For the genetic analysis, we considered synonymous mutations as selectively neutral, and used their rate to quantify whether
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Fig. 3 | HSPC phylogenies for three elderly adult donors. a–c, Phylogenetic
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Fig. 2. The phylogeny of the fourth elderly adult donor included in the study is
shown in Extended Data Fig. 5b.

non-synonymous mutations occurred at equivalent or elevated rates
(dN/dS ratio, with dN/dS > 1.0 denoting a tilt towards positive selection)—this was undertaken gene-by-gene and across all coding genes collectively37 (Supplementary Tables 6, 7). Estimating dN/dS gene by gene
identified three genes under positive selection: DNMT3A (q = 2.7 × 10−11),
ZNF318 (q = 1.2 × 10−6) and HIST2H3D (q = 0.086) (Extended Data Fig. 9a,
Supplementary Table 8). DNMT3A is a well-known myeloid cancer gene
with 23 mutations in our dataset, of which 13 were in expanded clades.
The age of occurrence of expanded DNMT3A mutations could be estimated from the trees: 2 were acquired before 10 years of age, 3 were
acquired before 20 years of age, and the remainder were acquired
before 40 years of age. Screening 534 acute myeloid leukaemia (AML)
genomes38,39 for variants in ZNF318 and HIST2H3D identified only one
possible oncogenic mutation in ZNF318 (Supplementary Table 9), showing that although these variants are under selection in HSC/MPPs, they
do not necessarily contribute to malignancy.
The genome-wide estimate of dN/dS was significantly higher, at 1.06
(95% confidence interval 1.03–1.09; Extended Data Fig. 9b), a value
that remained almost unchanged after evaluating potential biases
(Supplementary Methods). This value equates to 1 in 18 (range: 1 in 34 to
1 in 12) non-synonymous coding mutations in the dataset being drivers
(defined as any mutation under positive selection). Estimated dN/dS
ratios were almost identical in young and old individuals (1.06 and 1.05,
respectively), suggesting that the fraction of non-synonymous mutations (approximately 5%) under positive selection does not change with
age. Given that the overall mutation rate is constant, driver mutations
therefore enter the HSC pool at a constant rate throughout life, and
the expected number of driver mutations per cell increases linearly
with age.

Converting dN/dS ratios to estimated numbers of driver mutations revealed that each adult studied typically had more than 100
driver mutations among the colonies sequenced (Extended Data
Fig. 9c). These numbers are considerably higher than the number of
non-synonymous mutations identified in known cancer genes. This
implies that mutations under positive selection in normal HSCs affect a
wider set of genes than usually assessed, as suggested by other studies15,
and corroborates our observation that many clonal expansions in the
elderly occur in the absence of mutations in known cancer genes.
Loss of chromosome Y (loss of Y) was a frequent occurrence in older
males in our cohort. Loss of Y has been described in bulk blood samples
from ageing men, correlating with all-cause mortality23. Notably, in our
data, loss of Y showed frequent parallel evolution—the oldest male in
our study, aged 81 years, had at least 62 independent loss of Y events
across the phylogeny. Furthermore, loss of Y was significantly correlated with clonal expansion (P < 0.001; Extended Data Fig. 9d)—several
expanded clades in our dataset exhibited loss of Y, often without known
point mutation drivers, even in younger males (Figs. 2, 3, Extended
Data Fig. 5). Negative selection acting on loss of Y is likely to be less
stringent than on loss of autosomes; neverthelessa, that loss of Y generates significantly larger clones than euploid HSCs suggests that it is
also under positive selection, corroborating mouse models showing
Y-linked KDM6C suppresses leukaemogenesis40.

Modelling positive selection in HSCs
The genetic analysis suggests that positive selection is pervasive in HSCs,
but whether positive selection can completely explain the observed
phylogenies remains unclear. To address this, we used ABC modelling
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combined Nτ of both long-term HSC and short-term HSC/MPP compartments.
The trajectory line is shaded light grey where there is a complete absence of
coalescent events and the estimates are therefore inaccurate. The red line
shows the Bayesian (maximum posterior density) estimate of Nτ. b, Results
from approximate Bayesian inference of population size over the first
(non-shaded) part of life for each individual. The blue line represents the prior
density of Nτ and the red line represents the posterior density. The vertical grey
line denotes the peak Nτ for each donor; values are shown above each plot.

to infer HSC dynamics (Supplementary Note 1), with three aims: (1) to
assess whether clone-specific positive selection can explain apparently
abrupt loss in clonal diversity after age 70; (2) to estimate the rate at
which driver mutations enter the HSC pool; and (3) to estimate the distribution of fitness effects, defined as the excess average growth rate per
year of a clone with the driver over that of wild-type HSCs (denoted as s,
with s = 0 indicating neutrality; Extended Data Fig. 10, Supplementary
Methods). Simulations showed that mutations with fitness effects s < 5%
are unlikely to expand to more than 1% of HSCs over a human lifespan
(Extended Data Fig. 10d), so were not further considered.
ABC modelling showed that our observed trees could be closely emulated (Extended Data Figs. 11, 12) and carry sufficient information to estimate occurrence rate and fitness effects of driver mutations (Fig. 5c,
Extended Data Fig. 13a). From the ABC modelling, we estimated that
driver mutations enter the HSC compartment at 2.0 × 10−3 per HSC per
year. The estimate obtained from the genetic analysis, based on dN/dS, was
of drivers accruing at 3.6–10.0 × 10−3 per HSC per year, an estimate which
includes drivers with s < 5% present in colonies. Thus, even though the
ABC estimates derive only from branch structures of the phylogenies and
the genetic analysis relies only on non-synonymous versus synonymous
mutations, the two approaches concur in implying much higher rates of
driver mutation occurrence than estimated from bulk sequencing studies.

The ABC modelling generates simulations of HSC clonal dynamics
across a lifetime, which enables us to track how phylogenetic trees for
a given avatar would appear when sampled at different ages. In these
avatars, we found that there was typically a sharp change towards oligoclonal haematopoiesis after 60 years of age (Fig. 5d, Extended Data
Figs. 12, 13b), demonstrating that lifelong accumulation of drivers
triggering slow but inexorable exponential expansions causes abrupt
loss of clonal diversity in the elderly.
For fitness effects, the distribution most consistent with the data had
a preponderance of moderate-effect drivers, with s in the range 5–10%,
but a heavy tail of rare drivers conferring greater selective advantage
(s > 10%) (Fig. 5c). For the 46 largest observed clones, we could directly
estimate their fitness effects from the patterns of coalescences within
their clade, resulting in estimates of s in the range of 10–30% (Fig. 5e,
Extended Data Fig. 11b). This shows that clones without known drivers can evolve comparable selective advantages to those with classic
driver mutations.
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Discussion
Our data suggest that age-associated loss of clonal diversity is orders of
magnitude more pervasive than estimated from previous studies4,5,10–12:
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Fig. 5 | Widespread positive selection in the HSC/MPP compartment of
normal individuals. a, Stacked bar plot of number and size of clades with a
clonal fraction above 1% per individual. Blue segments denote clones with no
known driver and red ones denote those with a known myeloid gene driver.
Numbers above each stack denote the total number of expanded clades in that
individual. b, Shannon diversity index calculated for each phylogeny from the
number of lineages present at 100 mutations of molecular time (equivalent to
the first few years after birth) and their abundance (number of colonies derived
from that lineage). c, Distribution of fitness effects for the driver mutations
entering the HSC population, as determined using the ABC modelling
approach. The point estimate for the shape and rate parameters of the gamma
distribution were shape = 0.47 and rate = 34 (univariate marginal maximum

posterior density estimates; Supplementary Fig. 14). The black line denotes the
median, interquartile range is shown in dark grey and 95% posterior intervals
are shown in light grey. d, Median, interquartile range, and 95% posterior
intervals for Shannon diversity indices calculated yearly for 10,000 HSC
population simulations run with the optimal parameter values from the ABC
modelling. e, Fitness effects within the HSC/MPP compartment are estimated
for clades with known driver mutations containing four or more HSC/MPP
colonies (per cent additional growth per year). Fitness effects are also
estimated for expanded clades without known drivers containing five or more
HSC/MPP colonies. Error bars show the 95% credibility intervals of inferred
fitness effects. Clade numbers are illustrated on the phylogenies in Extended
Data Fig. 11b.

(1) the prevalence of clones at more than 1% variant allele fraction (VAF)
is universal after age 70, not 10–20% prevalent as previously estimated;
(2) the number of expanded clones per individual is 10–20, not 1–2;
(3) the fraction of overall haematopoiesis accounted for by expanded
clones is 30–60%, not 3–5%; and (4) clonal expansions have their origins in mutations that occurred decades earlier, and not in old age.
Age-related phenotypes in blood include anaemia, loss of regenerative capacity, remodelling of the bone marrow microenvironment
and increased risk of blood cancer—phenotypes that sharply increase
in prevalence after 70 years of age. The link between known driver
mutations and blood cancer risk is clear4–6, with some evidence that
expanded clones with undiscovered drivers also increase leukaemia transformation14. However, cancer need not be the ineluctable
end-point of positive selection41, and addressing whether expanded
clones collectively driving a sizable fraction of haematopoiesis contribute to, for example, age-related loss of resilience to perturbation or
microenvironment remodelling would be of interest in future studies.

From an evolutionary perspective, ageing arises because the force of
natural selection rapidly reduces to zero at ages beyond which reproductive output is negligible—the ‘selective shadow’42. Our data illustrate
how an abrupt, qualitative change in tissue composition can occur
within this shadow as the result of lifelong, gradual accumulation of
molecular damage. HSCs acquire driver mutations with moderate fitness benefits at a steady rate throughout life, so the clonal expansions
they trigger, although exponential, take decades to gather momentum. Evolutionary pressure on germline variants in genes controlling
these dynamics—HSC population size and turnover, somatic mutation rates and distribution of fitness benefits—has historically acted
to maintain robust, polyclonal haematopoiesis until 60–70 years of
age, but no further. Thus, the distribution of fitness effects that we
infer (Fig. 5c) has precisely this shape because of that evolutionary
pressure—a right-shifted distribution with stronger drivers would cause
sufficiently frequent blood cancers (or other deleterious phenotypes)
in reproductively active humans to exert evolutionary pressure, but the
Nature | Vol 606 | 9 June 2022 | 349
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selective shadow means evolutionary pressure for driving the distribution further to the left peters out.
Clonal expansion with abrupt collapse of stem cell diversity may
be a feature of ageing that generalizes beyond human blood. Many
human organ systems studied to date, including skin43, bronchus44,
endometrium45,46 and oesophagus47,48, show age-related expansions
of clones with driver mutations. Spatial organization of these tissues
shapes their clonal dynamics, but selection for the same drivers in many
independent clones can generate convergent genotypes at similar overall burden to those reported here (Supplementary Note 2). Similarly,
oligoclonality occurs in elderly haematopoiesis in other mammalian
species, including mice49 and macaques50. With such ubiquity of driver
mutations—selected purely for their competitive advantage within
the stem cell compartment—and with the wholesale rewiring of cellular pathways they induce, it is feasible that they may contribute to
phenotypes of human ageing beyond the risk of cancer.
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Methods
Samples
In order to obtain representative data from across the whole human
lifespan, samples were obtained from three sources: (1) Stem Cell
Technologies provided frozen mononuclear cells (MNCs) from two
cord blood samples that had been collected with informed consent,
including for whole-genome sequencing (catalogue no. 70007).
(2) Cambridge Blood and Stem Cell Biobank (CBSB) provided fresh
peripheral blood samples taken with informed consent from two
patients at Addenbrooke’s Hospital (NHS Cambridgeshire 4 Research
Ethics Committee reference 07/MRE05/44 for samples collected
before November 2019 and Cambridge East Ethics Committee
reference 18/EE/0199 for samples collected from November 2019
onwards. (3) Cambridge Biorepository for Translational Medicine
(CBTM) provided frozen bone marrow with or without peripheral
blood MNCs taken with informed consent from six deceased organ
donors. Samples were collected at the time of abdominal organ collection (Cambridgeshire 4 Research Ethics Committee reference
15/EE/0152). All samples were collected under the approved studies
quoted, with informed consent to use the materials for the research
undertaken here and publish the results. Details of the individuals
studied and the samples they provided are illustrated in Fig. 1b, with
additional information in Supplementary Table 1.
No statistical methods were used to predetermine sample size. The
experiments were not randomized and the investigators were not
blinded to allocation during experiments and outcome assessment.
Isolation of MNCs from peripheral blood
MNCs were isolated using Lymphoprep density gradient centrifugation
(STEMCELL Technologies), after diluting whole blood 1:1 with PBS. The
red blood cell and granulocyte fraction of the blood was then removed.
The MNC fraction underwent red cell lysis using 1 incubation at 4 °C for
15 min with RBC lysis buffer (BioLegend). CD34 positive cell selection of
peripheral blood and cord blood MNC samples was undertaken using
the EasySep human whole blood CD34 positive selection kit (STEMCELL
Technologies). The kit was used per the manufacturer’s instructions,
but with only a single round of magnetic selection. Bone marrow MNCs
did not undergo CD34 positive selection prior to cell sorting.
Fluorescence-activated cell sorting
MNC or CD34 enriched samples were centrifuged and resuspended in
PBS/3%FBS containing an antibody panel consisting of: CD3/FITC, CD90/
PE, CD49f/PECy5, CD38/PECy7, CD33/APC, CD19/A700, CD34/APCCy7,
CD45RA/BV421 and Zombie/Aqua. Cells were stained (30 min at 4 °C)
in the dark before washing and resuspension in PBS/3%FBS for cell sorting. For all samples, HSC/MPP pool cells (Lin−CD34+CD38−CD45RA−)
were sorted using either a BD Aria III or BD Aria Fusion cell sorter (BD
Biosciences) at the NIHR Cambridge BRC Cell Phenotyping hub. The
gating strategy is illustrated in Extended Data Fig. 1b. The HSC/MPP
population was treated as a single entity and not further subclassified
in the analysis. The immunophenotypic HSC/MPP population includes
both long-term, intermediate-term and short-term HSCs as well as
multipotent progenitors, as demonstrated functionally in xenotransplantation assays51–54.
In a subset of individuals, a small number of HPCs (Lin−CD34+CD38+)
were also sorted. The antibody panel used is shown in Supplementary
Table 2. The HPC cells were treated as a single entity in the analysis and
not further subclassified. The immunophenotypic HPC compartment
includes predominantly myeloid and erythroid progenitors.
Single-cell colony expansion in vitro
Single phenotypic HSC/MPP or HPC cells were index sorted, as above,
into Nunc 96 flat-bottomed tissue culture plates (Thermofisher),
containing 100 μl supplemented StemPro medium (Stem Cell

Technologies) but no mouse cell feeder layer. The following supplements were added to promote proliferation and push differentiation
toward granulocyte, monocyte, erythroid and natural killer cell types:
StemPro Nutrients (0.035%, Stem Cell Technologies), l-glutamine
(1%, ThermoFisher), penicillin-streptomycin (1%, ThermoFisher)
and cytokines (SCF, 100 ng ml−1; FLT3, 20 ng ml−1; TPO, 100 ng ml−1;
EPO, 3 ng ml −1; IL-6, 50 ng ml −1; IL-3, 10 ng ml −1; IL-11, 50 ng ml −1;
GM-CSF, 20 ng ml−1; IL-2, 10 ng ml−1; IL-7, 20 ng ml−1; lipids, 50 ng ml−1).
Cells were incubated at 37 °C and the colonies that formed were
topped up with 50 μl StemPro medium plus supplements at 14 ± 2
days as necessary. At 21 ± 2 days, a visual size assessment of colonies was undertaken prior to collection of cells for DNA extraction.
Larger colonies (≥3,000 cells in size) were transferred to fresh U
bottomed 96 well plate (Thermofisher). The U bottomed plates
were then centrifuged (500g for 5 min), medium was discarded, and
the cells were resuspended in 50μl PBS prior to freezing at −80 °C.
Smaller colonies (less than 3,000 but more than 200 cells in size)
were collected into 96-well skirted LoBind plates (Eppendorf) and
centrifuged (800g for 5 min). Supernatant was removed to 5–10 μl
using an aspirator prior to DNA extraction on the fresh pellet. For
larger colonies DNA extraction was performed using the DNeasy
96 blood and tissue plate kit (Qiagen). The Arcturus Picopure DNA
Extraction kit (ThermoFisher) was used to extract DNA from the
smaller colonies. Both kits were used per the manufacturer’s instructions. Overall, 42–89% of the sorted HSC/MPP population in each
individual produced a colony. This is much more efficient than previously used methods of colonygrowth in semi-solid media, where
it is has been estimated that 10% of single HSC/MPPs will produce
a colony. In addition, analysis of cell surface markers showed there
was no immunophenotypic difference between sorted HSC/MPPs
that formed colonies and were sequenced, compared to those that
did not (Extended Data Fig. 1c, d).

Whole-genome sequencing of colonies
A recently developed low-input enzymatic fragmentation-based
library preparation method45,55 was used to generate whole-genome
sequencing libraries from 1–5 ng extracted DNA from each colony.
Whole-genome sequencing was performed at a mean sequencing coverage of 14× (8–35×) on either the Hiseq X or the NovaSeq platforms
(Illumina). BWA mem was used to align 150 bp paired end reads generated to the human reference genome (NCBI build 37; GRCh37d5).
Variant calling
CaVEMan (used for calling SNVs) and Pindel (used for calling small
indels) were run against an unmatched synthetic normal genome using
in-house pipelines45,56–58. Outputs were then filtered using several strategies to exclude library, sequencing and mapping artefacts. Structural
variants were called using GRIDDS59, with all variants confirmed by
visual inspection and by checking if they fit the distribution expected
based on the SNV-derived phylogenetic tree. Autosomal CNAs and X
chromosome CNAs in females were called using allele-specific copy
number analysis of tumours60 (ASCAT), which was run against a single sample selected from each individual. The matched sample was
selected to have a coverage > 15×, no loss of Y and to be a singleton in the
phylogenetic tree (no coalescences post-birth). The ASCAT output was
manually interpreted through visual inspection. ASCAT was unable to
accurately call copy number changes on the haploid sex chromosomes
in males. Therefore, we also ran the breakpoint analysis algorithm
BRASS61 to generate an intermediate file containing information on
binned read counts across 500-bp segments of the genome. A comparison of the mean coverage of the X and Y chromosomes was used
to call X or Y CNAs in individual samples, which were then validated by
visual inspection of read depth.
Full details of the variant calling strategies and filtering approaches
used are described in the Supplementary Information.
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Filtering at the colony level
As outlined in the main text, we removed some colonies from the
dataset due to low coverage (17 samples), being technical duplicates
(34 samples) and for showing evidence of non-clonality or contamination (7 samples). We used a peak VAF threshold of < 0.4 (after the
removal of in vitro variants) as well as visual inspection of the VAF
distribution plots to identify colonies with evidence of non-clonality
(Extended Data Fig. 2a–c). Visual inspection was particularly important
in the cord blood samples where there was greater variability in the
distribution of variant allele frequencies due to the lower mutation
burden. In these samples the VAF threshold of < 0.4 was therefore less
stringently applied.
Validation of mutation calls
Mutation spectrums were compared between the set of shared mutations (those present in two or more colonies), which are those we have
the greatest confidence in, and private mutations (present in only one
sample), in which we have lower confidence (Extended Data Fig. 2e).
The mutation spectrums are almost identical, providing evidence that
the private mutation set does not contain excess artefacts.
Mutation burden analysis
SNV and indel burden analysis was performed by first correcting the
mutation and indel burden to a sequencing depth of 30, by fitting
an asymptotic regression to the data (function NLSstAsymptotic,
R package stats) (Extended Data Fig. 2d). Subsequently, linear mixed
effects models were used to test for a linear relationship between age
and number of SNVs or number of indels (function lmer, R package
lme4). Number of mutations or indels per colony was regressed using
log-likelihood maximization and age as a fixed effect, with the interaction between age and donor as a random effect. Progenitor samples
were excluded from this analysis.
We also performed linear regression of age and mutation burden as
above broken down by age range. Using data from the two cord blood
donors and the youngest adult age 29 gives a rate of mutation accumulation of 17.56 per year (95% confidence interval 17.32–17.78). Using
data from just the 3 younger donors aged 29, 38, 48 and 63 gives a rate
of mutation accumulation of 17.21 per year (95% confidence interval
16.12–18.3). Linear regression of age and mutation burden using the
5 older donors aged 63, 75, 76, 77 and 81 gives a rate of mutation accumulation of 18.84 per (95% confidence interval 16.82–20.86). These
results are very consistent over different phases of life.
Telomere analysis
Telomere length for each colony sequenced on the Hiseq platform
(corresponding to the telomere length in the founding HSC/MPP or
HPC) was estimated from the ratio of telomeric to sub-telomeric reads
using the algorithm Telomerecat62. Colonies sequenced on the Novaseq
platform could not be used as telomeric reads were removed by a quality control step prior to bam file creation.
Linear mixed effects models were used to test for a linear relationship between age and telomere length across all the adults. Cord blood
samples were excluded due to possible non-linearity of the relationship
between age and telomere length in very early life63.
Normality testing of the telomere length distributions was performed
in R using the Shapiro-Wilk normality test (function shapiro.test) and
visualized using Q–Q plots and density plots (functions ggqqplot and
ggdensity). The percentage of outlying HSC/MPPs per individual was
calculated using the interquartile range criterion (all samples outside
the interval [q0.25 − 1.5 × IQR, q0.75 + 1.5 × IQR] are considered as outliers; IQR is the interquartile range; q0.25 and q0.75 are the 25th and 75th
centiles respectively) (function boxplot.stats). For all individuals, the
only outliers in the data had longer than expected rather than shorter
than expected telomeres.

Construction of phylogenetic trees
The key steps to generate the phylogenies shown in Figs. 2, 3 and
Extended Data Fig. 5 are as follows:
1. Generate a ‘genotype matrix’ of mutation calls for every colony within
a donor. Our protocol, based on whole-genome sequencing of single
cell-derived colonies, generates consistent and even coverage across
the genome, leading to very few missing values within this matrix
(ranging from 0.005 to 0.034 of mutated sites in a given colony across
different donors within our cohort). This generates a high degree of
accuracy in the constructed trees.
2. Reconstruct phylogenetic trees from the genotype matrix. This is a
standard and well-studied problem in phylogenetics. The low fraction of the genome that is mutated in a given colony (<1 per million
bases) coupled with the highly complete genotype matrix mean that
different phylogenetics methods produce reassuringly concordant
trees. We used the MPBoot algorithm64 for the tree reconstruction,
as it proved both accurate and computationally efficient for our
dataset.
3. Correct terminal branch lengths for sensitivity to detect mutations in
each colony. The trees generated in the previous step have branch
lengths proportional to the number of mutations assigned to each
branch. For the terminal branches, which contain mutations unique
to that colony, variable sequencing depth can underestimate the true
numbers of unique mutations, so we correct these branch lengths
for the estimated sensitivity to detect mutations based on genome
coverage.
4. Make phylogenetic trees ultrametric. After step 3, there is little more
than Poisson variation in corrected mutation burden among colonies
from a given donor. Since these colonies all derived from the same
timepoint, we can normalize the branch lengths to have the same
overall distance from root to tip (known as an ultrametric tree). We
used an ‘iteratively reweighted means’ algorithm for this purpose.
5. Scale trees to chronological age. Since mutation rate is constant across
the human lifespan, we can use it as a molecular clock to linearly scale
the ultrametric tree to chronological age.
6. Overlay phenotypic and genotypic information on the tree. The tip
of each branch in the resulting phylogenetic tree represents a specific colony in the dataset, meaning that we can depict phenotypic
information about each colony underneath its terminal branch (the
coloured stripes along the bottom of Figs. 2, 3). Furthermore, every
mutation in the dataset is confidently assigned to a specific branch
in the phylogenetic tree. This means that we can highlight branches
on which specific genetic events occurred (such as DNMT3A or other
driver mutations).
A complete explanation of the steps undertaken in each of these
stages, comparisons of different methods available and notes on the
different approaches to validate the phylogenetic trees are available
in the Supplementary Information.
Inferring HSC population size trajectory
The R package phylodyn65 provides a well-established approach to
inferring historic population size trajectories from the pattern of coalescent events (more specifically the density of these events in historic
time blocks) in a phylogenetic tree created from a random sample of
individuals in the population. Its use has been pioneered in pathogen
epidemiology65 and has also been previously applied to HSPC data from
a single individual66. Extended Data Figs. 6b, 7b show how phylodyn
can accurately recover simulated population trajectories using sample
sizes similar to those we have used and illustrates how the number of
coalescent events in a given time window in the tree informs on population size through time (assuming a constant rate of HSC symmetric
cell division and a neutrally evolving population). We used phylodyn to
infer historic changes in LT-HSC Nτ from the ultrametric phylogenies
of the four youngest adults in the cohort (Fig. 4a).

Simulations of complete HSC populations from conception to the
age of sampling were performed for each individual using the R package rsimpop67 (https://github.com/NickWilliamsSanger/rsimpop).
Rsimpop utilizes a birth-to-death model with specified somatic mutation accumulation rate and symmetric cell division rate, to simulate a
complete HSC population. Each cell within the population has a rate of
symmetric division and a rate of symmetric differentiation (or death).
Asymmetric divisions do not impact on the HSC phylogeny and are
not accounted for in the model. Full details are available in the Supplementary Information.

Approximate Bayesian computation
We evaluated several ABC models of population dynamics, including
both models of selectively neutral genetic drift within the HSC compartment (assessing the effects of changes in population size on phylogenetic trees) and models of positive selection among the HSCs. An
additional motivation for performing the Bayesian inferences on neutral
models was to enable us to perform posterior predictive checks (PPC),
with the aim of deciding whether the observed phylogenies are compatible with neutral models. Note that a separate donor-specific posterior
distribution was generated (sampled) for each donor (donor-specific
ABC), and a separate donor-specific posterior predictive p-value was
computed for each donor (donor-specific PPC). Each donor-specific ABC
for the neutral model was performed using the ABC rejection method (R
package abc)68–70. Further details, together with detailed mathematical
exposition, are provided in Supplementary Information.
We used the population trajectory from phylodyn to identify the
time period prior to the increase related to a ST-HSC/MPP contribution,
and the timing of the midlife and late-life fold-change in Nτ (Fig. 4a,
Supplementary Fig. 12). We used our data to inform our choices for the
time between symmetric cell divisions, which was set at one year (after
the initial population growth phase in the first few years of life). We set
the rate of mutation accumulation at 15 mutations per year with an
additional 1 mutation for every cell division (both of these were drawn
from a Poisson distribution centred on the input value).
Analysis of driver variants
Variants identified were annotated with Variation Annotation Generator
(VAGrENT) (https://github.com/cancerit/VAGrENT) to identify protein
coding mutations and putative driver mutations in each dataset71–77.
Supplementary Table 4 lists the 17 genes we have used as our top
clonal haematopoiesis genes (those identified by Fabre et al. as being
under positive selection in a targeted sequencing dataset of 385 older
individuals78), whose ‘oncogenic’ and ‘possible oncogenic’ mutations
(as assessed independently by E.M. and P.J.C.) are shown in Figs. 2, 3
and Extended Data Fig. 5. In the same table, we also list a more extensive
list of 92 clonal haematopoiesis genes derived from the literature37, 71, 72
that were interrogated. In order to explore a wider set of cancer gene
mutations we used the 723 genes listed in Cosmic’s Cancer Gene Census
(https://cancer.sanger.ac.uk/census).
dN/dS analysis
We used the R package dndscv37 (https://github.com/im3sanger/
dndscv) to look for evidence of positive selection in our dataset
(https://github.com/emily-mitchell/normal_haematopoiesis/5_dNdS/
scripts/all_DNDScv_final.Rmd). The dndscv package compares the
observed ratio of missense, truncating and nonsense to synonymous
mutations with that expected under a neutral model. It incorporates
information on the background mutation rate of each gene and uses
trinucleotide-context substitution matrices. The approach provides
a global estimate of selection in the coding variant dataset (Supplementary Table 7), from which the number of excess protein coding,
or driver mutations can be estimated. In addition, it identifies specific
genes that are under significant positive selection. Further details are
provided in Supplementary Information.

Chromosome Y loss analysis
We observe a series of phylogenetic trees from male individuals in
which some clades have lost the Y chromosome. By eye, these clades
seem to be larger than clades that have not lost Y. To test this formally,
we use a randomization or Monte Carlo test to define the null expected
distribution of clade size. For each Monte Carlo iteration, we draw
branches of the phylogenetic tree at random—one random branch
for each observed instance of Y loss. These branches are sampled
(with replacement) from the set of all extant branches at the matched
time-point in that individual, and the eventual clade size of that draw
measured. For each simulation, the geometric mean (to allow for the
log-normality of observed clade sizes) of clade sizes is calculated. We
can then compare the distribution of geometric means from the Monte
Carlo draws with the observed geometric mean.
Analysis of AML
Mutations in ZNF318 and HIST2H3D were identified in recently described
tumour whole-genome sequencing data from 263 patients with AML
and myelodysplastic syndromes seen at Washington University School
of Medicine in St Louis38. Sequencing, initial processing using the hg38
human reference genome, and full variant calling details for this dataset were described previously38. Briefly, identification of SNVs and
indels in ZNF318 and HIST2H3D was performed with Varscan2 run in
SNV and indel mode using custom parameters to enhance sensitivity (--min-reads2 = 3, --min-coverage = 6, --min-var-freq = 0.02, and
--p-value = 0.01), along with indel callers Pindel and Manta using default
parameters. Variant calls identified via these approaches were merged
and harmonized using a custom python script and annotated with VEP
using Ensembl version 90. Only one potentially pathogenic variant
was found in ZNF318. All identified variants are listed in Supplementary Table 8, the majority are likely to be rare germline variants as the
sequencing strategy did not incorporate a matched normal sample.
In addition, there were no variants in ZNF318 or HIST2H3D reported
in 200 cases of AML in the TCGA dataset79, compared to 51 cases with
DNMT3A mutations. Similarly of 71 AML cases in the JAMA study39 23
cases had DNMT3A mutations but none had ZNF318 or HIST2H3D mutations. Both studies used a tumour/normal WGS approach and reported
all somatic variants identified as part of their supplementary datasets.
Software
Programs and software used in the data analyses: R: version 3.6.1,
BWA-MEM: version 0.7.17 (https://sourceforge.net/projects/bio-bwa/),
cgpCaVEMan: version 1.11.2/1.13.14/1.14.1 (https://github.com/cancerit/CaVEMan), cgpPindel: version 2.2.5/3.2.0/3.3.0 (https://github.
com/cancerit/cgpPindel), Brass: version 6.1.2/6.2.0/6.3.0/6.3.4
(https://github.com/cancerit/BRASS), ASCAT NGS: version
4.2.1/4.3.3 (https://github.com/cancerit/ascatNgs), VAGrENT: version
3.5.2/3.6.0/3.6.1 (https://github.com/cancerit/VAGrENT), GRIDSS: version 2.9.4 (https://github.com/PapenfussLab/gridss), MPBoot: version
1.1.0 (https://github.com/diepthihoang/mpboot), cgpVAF: version
2.4.0 (https://github.com/cancerit/vafCorrect), dNdScv: version 0.0.1
(https://github.com/im3sanger/dndscv), Telomerecat: version 3.4.0
(https://github.com/jhrf/telomerecat), Rsimpop: version 2.0.4 (https://
github.com/NickWilliamsSanger/rsimpop), Phylodyn: version 0.9.02
(https://github.com/mdkarcher/phylodyn) and FlowJo: version 10.
Reporting summary
Further information on research design is available in the Nature
Research Reporting Summary linked to this paper.

Data availability
Raw sequencing data are available on the European Genome–Phenome
Archive under accession number EGAD00001007851). The main data
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needed to reanalyse or reproduce the results presented are available
on Mendeley at https://data.mendeley.com/datasets/np54zjkvxr/1.
See Supplementary Information for a guide to the specific file and
folder structure.

Code availability
All scripts, some smaller data matrices and custom code, including
step-by-step notebooks detailing the phylogenetic reconstruction for
each research subject, are available on github at https://github.com/
emily-mitchell/normal_haematopoiesis/.
50. Yu, K. R. et al. The impact of aging on primate hematopoiesis as interrogated by clonal
tracking. Blood 131, 1195–1205 (2018).
51. Notta, F. et al. Isolation of single human hematopoietic stem cells capable of long-term
multilineage engraftment. Science 333, 218–221 (2011).
52. Huntsman, H. D. et al. Human hematopoietic stem cells from mobilized peripheral blood
can be purified based on CD49f integrin expression. Blood 126, 1631–1633 (2015).
53. Laurenti, E. et al. CDK6 levels regulate quiescence exit in human hematopoietic stem
cells. Cell Stem Cell 16, 302 (2015).
54. Notta, F. et al. Distinct routes of lineage development reshape the human blood hierarchy
across ontogeny. Science 351, aab2116 (2015).
55. Ellis, P. et al. Reliable detection of somatic mutations in solid tissues by laser-capture
microdissection and low-input DNA sequencing. Nat. Protoc. 16, 841–871 (2021).
56. Jones, D. et al. cgpCaVEManWrapper: simple execution of CaVEMan in order to detect
somatic single nucleotide variants in NGS data. Curr. Protoc. Bioinformatics 56,
15.10.1–15.10.18 (2016).
57. Raine, K. M. et al. cgpPindel: identifying somatically acquired insertion and deletion
events from paired end sequencing. Curr. Protoc. Bioinformatics 52, 15.7.1–15.7.12 (2015).
58. Coorens, T. H. H. et al. Extensive phylogenies of human development inferred from
somatic mutations. Nature 597, 387–392 (2021).
59. Cameron, D. L. et al. GRIDSS: sensitive and specific genomic rearrangement detection
using positional de Bruijn graph assembly. Genome Res. 27, 2050–2060 (2017).
60. Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl Acad. Sci. USA
107, 16910–16915 (2010).
61. Campbell, P. J. et al. Identification of somatically acquired rearrangements in cancer
using genome-wide massively parallel paired-end sequencing. Nat. Genet. 40, 722–729
(2008).
62. Farmery, J. H. R. et al. Telomerecat: a ploidy-agnostic method for estimating telomere
length from whole genome sequencing data. Sci. Rep. 8, 1300 (2018).
63. Frenck, R. W., Blackburn, E. H. & Shannon, K. M. The rate of telomere sequence loss in
human leukocytes varies with age. Proc. Natl Acad. Sci. USA 95, 5607–5610 (1998).
64. Thi Hoang, D. et al. MPBoot: fast phylogenetic maximum parsimony tree inference and
bootstrap approximation. BMC Ecol. Evol. 18, 11 (2018).
65. Lan, S., Palacios, J. A., Karcher, M., Minin, V. N. & Shahbaba, B. An efficient Bayesian
inference framework for coalescent-based nonparametric phylodynamics. Bioinformatics
31, 3282–3289 (2015).
66. Lee-Six, H. & Kent, D. G. Tracking hematopoietic stem cells and their progeny using
whole-genome sequencing. Exp. Hematol. 83, 12–24 (2020).
67. Williams, N. et al. Phylogenetic reconstruction of myeloproliferative neoplasm
reveals very early origins and lifelong evolution. Preprint at https://doi.org/10.1101/
2020.11.09.374710 (2020).
68. Csilléry, K., François, O. & Blum, M. G. B. Abc: An R package for approximate Bayesian
computation (ABC). Methods Ecol. Evol. 3, 475–479 (2012).
69. Beaumont, M. A., Zhang, W. & Balding, D. J. Approximate Bayesian computation in
population. genetics. Genetics 162, 2025–2035 (2002).
70. Gelman, A. et al. Bayesian Data Analysis (CRC Press, 2004).
71. Rheinbay, E. et al. Analyses of non-coding somatic drivers in 2,658 cancer whole
genomes. Nature 578, 102–111 (2020).
72. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new
cancer-associated genes. Nature 499, 214–218 (2013).
73. Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature
578, 94–101 (2020).

74.
75.

76.
77.
78.
79.

Vaser, R., Adusumalli, S., Ngak Leng, S., Sikic, M. & Ng, P. C. SIFT missense predictions for
genomes. Nat. Protoc. 11, 1–9 (2016).
Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting functional effect of human
missense mutations using PolyPhen-2. Curr. Protoc. Hum. Genet. https://doi.
org/10.1002/0471142905.hg0720s76 (2013).
Nei, M. & Gojobori, T. Simple methods for estimating the numbers of synonymous and
nonsynonymous nucleotide substitutions. Mol. Biol. Evol. 3, 418–426 (1986).
Greenman, C., Wooster, R., Futreal, P. A., Stratton, M. R. & Easton, D. F. Statistical analysis
of pathogenicity of somatic mutations in cancer. Genetics 173, 2187–2198 (2006).
Fabre, M. A. et al. The longitudinal dynamics and natural history of clonal
haematopoiesis. Nature https://doi.org/10.1038/s41586-022-04785-z (2022).
The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of
adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074 (2013).

Acknowledgements This work was supported by the WBH Foundation. Investigators at the
Sanger Institute are supported by a core grant from the Wellcome Trust. P.J.C. was a Wellcome
Trust Senior Clinical Fellow (WT088340MA) until 2020. N.M. was supported by a DFG Research
Fellowship (ME 5209/1-1). Work in the D.G.K. laboratory is supported by a Bloodwise Bennett
Fellowship (15008), a Cancer Research UK Programme Foundation Award (DCRPGF\100008),
and a European Research Council Starting Grant (ERC-2016-STG–715371). Work in the A.R.G.
laboratory is supported by the Wellcome Trust, Bloodwise, Cancer Research UK, the Kay
Kendall Leukaemia Fund, and the Leukemia and Lymphoma Society of America. Work in the
E.L. laboratory is supported by a Wellcome Trust Sir Henry Dale Fellowship, BBSRC and a
European Haematology Association Non-Clinical Advanced Research Fellowship. The E.L. and
A.R.G. laboratories are supported by a core support grant from the Wellcome Trust and
Medical Research Council to the Cambridge Stem Cell Institute. K.M. is supported by the
Chan-Zuckerberg Initiative. K.C. is supported by a Wellcome Investigator award
(210755/Z/18/Z). We thank the Cambridge Blood and Stem Cell Biobank; the Cambridge
Biorepository for Translational Medicine for access to human bone marrow and matched
peripheral blood; and the Cambridge NIHR BRC Cell Phenotyping Hub for their flow cytometry
services and advice. We acknowledge further assistance from the National Institute for Health
Research Cambridge Biomedical Research Centre and the Cambridge Experimental Cancer
Medicine Centre. We are grateful to the donors, families of donors and the Cambridge
Biorepository for Translational Medicine for the gift of tissues. We thank T. Ley for his help with
analysis of AML genomes. For the purpose of Open Access, the author has applied a CC-BY
public copyright license to any Author Accepted Manuscript version arising from this
submission. This research was supported by the NIHR Cambridge Biomedical Research Centre
(BRC-1215-20014). The views expressed are those of the authors and not necessarily those of
the NIHR or the Department of Health and Social Care.
Author contributions P.J.C., E.L. and E.M. designed the experiments. E.L., J.N., A.R.G. and P.J.C.
supervised the project. E.M. performed cell sorting and colony growth with advice from N.M.,
E.F.C., D.G.K. and E.L. and assistance from M.D. and D.H. E.M. performed data curation, data
analyses, and modelling with advice and assistance from M.S.C., N.W., K.J.D., T.M., T.H.H.C.,
H.M., H.L.-S., M.A.F., F.A., A.C., G.S.V., I.M., M.R.S., A.R.G., J.N., E.L. and P.J.C. N.W. and J.N.
developed the simulator used for HSC population modelling. K.J.D. developed and performed
posterior predictive model checking. H.J. performed structural variant analysis. T.M.
performed loss-of-Y analysis; M.S.C. performed phylogeny benchmarking; D.H.S. performed
AML genome analysis. K.M., K.C. and K.S.P. collected and processed samples and J.B. assisted
with project management. E.M., J.N., E.L. and P.J.C. wrote the manuscript. All authors reviewed
and edited the manuscript.
Competing interests D.H.S. has received consultancy fees from Wugen. G.S.V. has received
consultancy fees from STRM.BIO and is a remunerated member of AstraZeneca’s Scientific
Advisory Board. D.G.K. has received research funding from STRM.BIO.
Additional information
Supplementary information The online version contains supplementary material available at
https://doi.org/10.1038/s41586-022-04786-y.
Correspondence and requests for materials should be addressed to Jyoti Nangalia,
Elisa Laurenti or Peter J. Campbell.
Peer review information Nature thanks Sudhir Kumar, Johannes Reiter and the other,
anonymous reviewers for their contribution to the peer review of this work. Peer review reports
are available.
Reprints and permissions information is available at http://www.nature.com/reprints.

Extended Data Fig. 1 | Flow-sorting strategy for single HSC/MPP and HPC
cells. a, Experimental approach. b, Sorting of single human HSC/MPP and
HPCs from cord blood, peripheral blood and bone marrow. Cells were stained
with the panel of antibodies in Supplementary Table 1 then single HSC/MPP or
HPCs were index sorted according to the strategy depicted into individual
wells of 96 well plates. Image created with FlowJo v10. c, Colony forming
efficiency per individual of all single HSPCs sorted. d, Box-and-whisker plots
showing fluorescence intensity for different cell surface markers used to

define human HSCs, with different patients in rows. CD90 and CD49f are
markers used to define the short and long term HSC subsets, which were
included in our panel but were not used in sorting. Cells that produced colonies
large enough to sequence are shown in teal; cells that did not form large enough
colonies to sequence are in orange. The horizontal lines denote the median, the
boxes the interquartile range and the whiskers the range. The number (n) of
‘sequenced’ (teal) and ‘not sequenced’ (orange) colonies included for each
individual are shown to the right of each panel.
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Extended Data Fig. 2 | See next page for caption.

Extended Data Fig. 2 | Quality assurance of mutation calls. a, Histogram of
VAFs for a typical sample in the dataset, showing a tight distribution around 50%,
as expected for an uncontaminated clonal sample derived from a single cell. The
variants with VAFs < 0.2 represent in vitro acquired mutations and sequencing
artefacts and were removed using a VAF-based filtering strategy with a cut off of
0.2 (red line). b, VAF distribution of variants after filtering steps had been
applied. The red line shows the peak VAF and the dashed grey line shows the
threshold peak VAF for excluding samples as being non-clonal / contaminated.
c, Histogram of VAFs for a colony that was seeded by 2 cells showing a median VAF
around 25%. Colonies showing evidence of non-clonality in this way were
excluded from downstream analysis using a peak VAF cut off of 0.4. d, Left-hand

plot shows the relationship between raw mutation counts per colony for one
individual post filtering and sequencing depth. The black line depicts an
asymptotic regression line fitted to the raw data. Right-hand plot shows the
adjusted mutation burdens per colony after asymptotic regression correction.
e, Trinucleotide context mutation spectra of private (top plot) and shared
variants (bottom plot) for one individual. The spectra are extremely similar,
showing the variant filtering strategy used is robust and prevents excess
artefacts in the private variant set. f, Trinucleotide mutation spectrums for each
individual created from all variants post filtering. The results are consistent
between the two cord blood donors and all the adult donors.
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Extended Data Fig. 3 | Approach to phylogeny construction. a, Raw
phylogeny for KX003 (81-year male) derived directly from MPBoot. The input to
MPBoot is a genotype matrix of all variant calls shared by more than 1 colony
from an individual. b, Phylogeny with edge lengths proportional to the number
of mutations assigned to the branch using original count data and the tree_mut
package. c, Phylogeny with raw mutation count branch lengths adjusted for

sequencing depth of the sample using sensitivity for germline variant calling.
d, Phylogeny with adjusted branch lengths converted to ultrametric form
(equal branch lengths). One axis shows mutation number, the other axis shows
the equivalent estimated age in years, which is possible due to the linear
accumulation of mutations in HSPCs with time. All tips end at age 81, the age at
the time of sampling.

Extended Data Fig. 4 | Mutational burden. a, Regression of number of single
nucleotide variants (SNVs) in HSCs (red line) compared to HPCs (blue line).
Grey shading indicates the 95% CI. The estimated difference in burden,
together with the t-value is above the plot. The t-value of 1.54 demonstrates
non-significance of the difference. b, Phylogenies depicted for the individuals
with clonally expanded structural variants (SVs). The bar at the bottom
highlights cells with one of the three classes of structural variant. The exact
variant breakpoints can be found in Supplementary Table 3. c, Plot showing the

percentage of HSC/MPP cells that have outlying telomere lengths per
individual. Outliers were identified using the Interquartile Range criterion.
There were no outliers with shorter than expected telomeres in any individuals,
such that this data only reflects the percentage of cells with longer than
expected telomeres. The blue line shows a regression of percentage outlying
telomere lengths with age. This shows a significant negative correlation
(t-value and p-value shown).
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Extended Data Fig. 5 | Additional HSPC phylogenies for one young and one elderly adult donor. Phylogenetic trees were constructed and presented as
described for Fig. 2.

Extended Data Fig. 6 | See next page for caption.
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Extended Data Fig. 6 | Interpretation of young adult HSPC phylogenies.
a, Trajectories of Nτ used as input to rsimpop for the simulations to create
phylogenies in b. Note the Y axis depicting Nτ is on a log scale. b, Phylogenies
created by randomly sampling 380 cells from the final full simulated
population of between 100,000 cells (Phylogeny 1) and 1,000,000 cells
(Phylogeny 4). Phylogenies 1 to 3 are derived from simulations of the HSC
population in a 30-year-old, while phylogeny 4 is derived from a simulation of
the HSC population in an 80-year-old. Each simulation has an initial Nτ of 100. In
all cases Nτ is the same as the population size (N) as the generation time (τ) in all
simulations is fixed at 1. The blue boxes indicate the period of time in which the

population size is increased. The phylodyn trajectories to the right of each
simulated phylogeny use the pattern of coalescent events to recover the input
trajectories for Nτ. The blue line marks the time of change in Nτ. In all cases the
initial part of the trajectory is able to correctly estimate Nτ at 100,000.
However, in Phylogeny 3 where there is a complete absence of coalescent
events once the population size is increased, phylodyn loses resolution and
wildly overestimates the value of Nτ. c, Real trees with red boxes highlighting
the last 10–20 years prior to sampling, where the relative number of coalescent
events is decreased (meaning the estimated Nτ is larger).

Extended Data Fig. 7 | See next page for caption.

Article
Extended Data Fig. 7 | Interpretation of elderly adult HSPC phylogenies.
a, Plots illustrating the timing of acquisition of driver mutations and onset of
clonal expansions respectively. These timings are inferred from the timing of
the corresponding branches in the phylogenies depicted in Figs. 2, 3 and
Extended Data Fig. 5. Bars are colours by gene mutation or blue for expanded
clades with no known driver. Age 0 denotes the time of birth and black dots
illustrate the age at sampling. b, Phylogenies created by randomly sampling
380 cells from the final full simulated population. As with the previous
simulations, Nτ ~ population size because the time between symmetric
self-renewal divisions is set at 1 year. In both simulated phyologenies the final

population is 100,000 cells in size, but Phylogeny 2 has been created from a
population that underwent a bottleneck in size to and Nτ of 10,000 cells
between the ages of 35 and 50. This period of time over which the population
size was reduced can be visualised in the blue box which highlights the
increased density of coalescent events in this time block. The phylodyn
trajectories are able to accurately recover information on changes in Nτ of the
HSC population over time. c, Real HSC/MPP phylogeny for KX003 (81-year-male)
with PB HSC/MPP terminal branches coloured red (BM HSC/MPP branches
remain black). The CF of the largest clade is shown for PB and BM cells.

Extended Data Fig. 8 | See next page for caption.
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Extended Data Fig. 8 | Modelling HSC populations incorporating only
changes in Nτ, without positive selection. a, Overview of modelling
approach used to estimate Nτ alone in the young adult individuals and to
investigate whether changes in Nτ could explain the observed clade size
distribution in the elderly adult individuals. These simulations were run using a
neutral model (that is, no acquisition of driver mutations), with Nτ being the
only parameter to change over time. For the young adult individuals Nτ was
estimated for two time-blocks (time before and after population increase due
to ST-HSC/MPP contribution). For the elderly adult individuals Nτ was
estimated for three time-blocks as the phylodyn plots predicted a population
‘bottleneck’ (Supplementary Fig. 12) was the most parsimonious way to
recreate the observed change in coalescence density over life. b, Plots showing
the posterior predictive distribution of the difference between the simulated
chi-squared discrepancy and the observed chi-squared discrepancy, for each
donor individual under a neutral model incorporating change in population

size. For each donor, the posterior predictive distribution of the difference
between predictive (simulated) and observed chi-squared discrepancy is
represented as a histogram based on a Monte Carlo sample of 1,000,000
simulated phylogenies, drawn from the posterior predictive distribution.
The proportion of simulated phylogenies which lie to the right of zero (red line)
is a Monte Carlo estimate of the posterior predictive p-value (the probability
that the predictive chi-squared discrepancy exceeds the observed chi-squared
discrepancy under the neutral model). In the case of the four young adult
individuals, the proportion of simulated phylogenies which lie to the right
of 0 (red line) is close to 0.5, indicating that the simple neutral models
(incorporating changes in Nτ over life) predict trees that have similar clade size
distributions to our observed trees. In contrast, for the four elderly adults, the
proportion of simulated phylogenies which lie to the right of 0 is very small
(Less than 0.05), demonstrating that the neutral models are, on their own,
unable to recreate trees with similar clade size distributions to those observed.

Extended Data Fig. 9 | Positive selection in blood. a, Lolliplot plots to show
the sites of variants in the dataset in the three genes under significant positive
selection according to dN/dS. Thick grey bars denote locations of conserved
protein domains. b, dN/dS maximum likelihood estimates for missense,
nonsense, truncating and all mutations in the complete dataset (n = 25,888
coding mutations) and for all mutations in the young (individuals aged < 65 year)
and old (individuals aged > 75 years) datasets analysed separately. The boxes
show the estimate with whiskers showing the 95% CI. The numbers to
the left give the numeric values for the estimates with 95%CI in brackets.
c, Estimated number of driver mutations in the different datasets. The boxes

show the estimate with whiskers showing the 95% CI. The numbers to the left
give the numeric values for the estimates with 95%CI in brackets. ‘n’ is the
number of cells included in each dataset. d, Results of a randomisation / Monte
Carlo test to define the null expected distribution of clade size for cells with
loss of Y. This null distribution of geometric means from 2000 simulations is
shown (histogram) together with the observed geometric mean of clades with
Y loss (vertical blue line). The observed value significantly outlies the expected
distribution showing that clades with Y loss are significantly larger than would
be expected by chance.
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Extended Data Fig. 10 | See next page for caption.

Extended Data Fig. 10 | Modelling of HSC populations incorporating
positive selection. a, Overview of modelling approach used to estimate the
shape and rate of the gamma distribution of selection coefficients from which
‘driver mutations’ are drawn, and the number of driver mutations drawn from
this distribution (using a selection coefficient threshold of > 0.05) that are
entering the HSC population per year. For these simulations Nτ was fixed at
100,000 and therefore only summary statistics for the first 3 timepoints were
used to assess how well a given simulation for an individual resembled the
observed tree. b, Plot showing maximum posterior density estimates of the
rate and shape parameters of the gamma distribution for selection coefficients
(pink line) obtained using Approximate Bayesian computation. Blue/green

lines show how altering the rate and shape parameters affect the gamma
distribution. c, Plot showing how changing the shape of the gamma
distribution of selection coefficients (each line has a different shape) alters the
probability of a driver gene fixing in the population. Reducing the shape below
0.1 does not affect the probability of driver gene fixation and therefore was the
lower limit of the shape prior. d, Plot showing how the probability of detecting a
clone with CF 2.5% changes over time for different selection coefficients. There
is only a probability of 0.1 of being able to identify a driver mutation with a
selection coefficient of 0.05 that entered the population at birth. We therefore
used a lower threshold of 0.05 for the driver mutation selection coefficients.
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Extended Data Fig. 11 | See next page for caption.

Extended Data Fig. 11 | Driver modelling results and expanded clade
annotation. a, Plots showing the posterior predictive distribution of the
difference between the predictive (simulated) chi-squared discrepancy and the
observed chi-squared discrepancy, for each donor individual under the simple
positive selection model. For the definition of the chi-squared discrepancy,
and details of how the posterior predictive p-values are estimated,
see Supplementary Information “Posterior predictive model checking (PPC)
methods which can be applied to Approximate Bayesian Computations (ABC)”,
Sections 1, 2 and 5. In these plots, the chi-squared discrepancy is computed
from summary statistics evaluated at the first 3 (out of 4 equally spaced)
timepoints on the phylogeny obtained from the specified donor (Extended
Data Fig. 8). For each donor, the posterior predictive distribution of the
difference between predictive (simulated) and observed chi-squared
discrepancy is represented as a histogram based on a Monte Carlo sample of at
least 100,000 simulated phylogenies, drawn from the posterior predictive
distribution. The proportion of simulated phylogenies which lie to the right of
zero (red line) is a Monte Carlo estimate of the posterior predictive p-value (the
probability that the predictive chi-squared discrepancy exceeds the observed
chi-squared discrepancy under the positive selection model). Those p-values
written in grey text are based on chi-squared discrepancies computed from

summary statistics evaluated at the first 2 (out of 4 equally spaced) timepoints.
Notice that these p-values are all above the 0.05 threshold, indicating that
observed phylogenies (up to the second time point) are compatible with the
simple positive selection model. Those p-values written in blue text are based
on chi-squared discrepancies computed from summary statistics evaluated at
the first 3 (out of 4 equally spaced) timepoints. Notice that all but two observed
phylogenies (up to the third time point) are compatible with this positive
selection model. These p-values indicate that, once the third time point is
included, the phylogenies of two of the younger individuals (38 year-old and
48 year-old) are no longer compatible with the positive selection model. Notice
that these two donors also exhibit the most striking increase in population size
from the middle part of the population trajectory onwards (Fig. 4a). When all
four timepoints are included, the phylogenies of 5 out of 8 donors have become
incompatible with the positive selection model (data not shown). Only the
phylogenies from the donors of ages 77, 76 and 29, remain compatible with the
positive selection model. This suggests that the current positive selection
model does not adequately account for the population processes towards the
time of sampling. b, Phylogenies of the four adults aged > 70 labelled with
driver mutations and clade ID annotations as used in Fig. 5d.
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Extended Data Fig. 12 | See next page for caption.

Extended Data Fig. 12 | Positive selection over life. Four consecutively
simulated phylogenies of 380 cells sampled from a population of 100,000 cells
that has been maintained at a constant Nτ over life, with incorporation of
positively selected ‘driver mutations’. The driver mutations have a fitness
effect > 5% (drawn from a gamma distribution with shape = 0.47 and rate = 34)
and enter the population at a rate of 200 per year. These are the maximum
posterior density estimates of the rate and shape parameters obtained using
the ABC method. The inclusion of these driver mutations is able to recapitulate
a similar clade size distribution to that observed in the real HSPC phylogenies
of the observed individuals across the whole age range. However, including
driver mutations does not fully recapitulate the observed lack of coalescent
events in the last 10–15 years of life, showing that an increase in Nτ over this time

is also required to fully recreate the patterns of coalescences in the real
phylogenies. Driver mutations are marked with a symbol and their descendent
clades are coloured. In all cases Nτ is the same as the population size (N) as the
generation time (τ) in all simulations is fixed at 1 year. The symbols / colours are
not consistent for driver mutations between plots. The largest clades are
therefore coloured in a consistent way beneath the plots to show how their size
changes over time. The simulated phylogenies illustrate the complex clonal
dynamics that can occur in later life as a result of clonal competition. While the
majority of clades continue to expand, others stay relatively stable and some
reduce in size. The phylogenies also show that by the age of 80 typically > 90%
of HSCs in the population carry at least one driver mutation.
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Extended Data Fig. 13 | Driver modelling parameter and driver acquisition
estimates. a, Posterior distributions for the three driver modelling parameters:
1) Number of ‘driver’ mutations with a fitness effect > 5% entering HSC
population of 100,000 cells per year, 2) Rate of gamma distribution of fitness
effects, 3) Shape of gamma distribution of fitness effects. Black lines show peak
estimates. b, Plot showing the median, interquartile range, and 1st and 99th

percentiles for proportion of HSC population with drivers calculated yearly for
10,000 HSC population simulations run utilising the optimal parameter values
for driver acquisition rate and fitness effects derived from the ABC modelling
approach. The point estimate for the shape and rate parameters of the gamma
distribution were shape = 0.47, rate = 34. The point estimate for the number of
drivers with s>5% entering population per year = 200.

